Cyclosporin A and Epirubicin

The combination of cyclosporin A and epirubicin represents a therapeutic approach that has been studied particularly in the context of overcoming multidrug resistance in cancer treatment. Based on the search results, I can provide the following information about this drug combination. ## Mechanism and Clinical Application Cyclosporin A is used in combination with epirubicin to potentially enhance the effectiveness of chemotherapy by inhibiting P-glycoprotein-mediated multidrug resistance (MDR)[1]. This combination has been studied in various cancer types, including neuroblastoma, Ewing's sarcoma, rhabdomyosarcoma, osteosarcoma, and others[1]. The combination works through cyclosporin's ability to act as a competitive P-glycoprotein inhibitor, which can prevent the efflux of chemotherapeutic agents like epirubicin from cancer cells, thereby increasing intracellular drug concentrations and potentially overcoming resistance[1][2]. ## Clinical Evidence In one study, sixteen children and young adults with various tumor types who had progressed or relapsed following previous treatments were treated with high-dose cyclosporin combined with epirubicin, vincristine, and etoposide (EVE)[1]. The major toxicities observed were acute reactions to cyclosporin and myelosuppression, while renal and hepatic toxicity was rarely severe and always transient[1]. Partial responses were observed in two patients (one with rhabdomyosarcoma and one with Ewing's sarcoma)[1]. Another therapeutic approach involves epirubicin conjugated to monoclonal antibodies targeting HER2/neu or EGFR, which has shown synergistic anti-neoplastic activity against chemotherapeutic-resistant breast cancer when used with competitive P-glycoprotein inhibitors[2]. ## Drug Interactions Epirubicin has numerous drug interactions - 679 drugs are known to interact with it, including 112 major, 558 moderate, and 9 minor interactions[3]. Additionally, there are 5 disease interactions and 1 alcohol/food interaction with epirubicin[3]. Cyclosporine is an immunosuppressant used in organ and bone marrow transplants as well as inflammatory conditions[4]. It works by inhibiting cyclophilin, a peptidyl-prolyl cis-trans isomerase[4]. For metastatic breast cancer, a combination of epirubicin and cyclophosphamide (EC) has been studied in clinical trials, showing comparable efficacy to epirubicin and paclitaxel (EP) in terms of progression-free survival and overall survival[5].